According to a study, a booster vaccination with the vaccine from Biontech / Pfizer restores a high level of vaccination protection. When examining more than 10,000 people aged 16 and over, who had previously been immunized twice with the Biontech vaccine, the level of vaccination protection after the booster dose was as high as after the second vaccination, said the US pharmaceutical giant Pfizer and its Mainz partner Biontech.
Large-scale study proves success
According to the two companies, a third stab with the corona vaccine showed an effectiveness of over 95 percent in the study. Safety concerns or unknown side effects had not been observed, said the Mainz-based company and its US partner, citing a series of tests.
The dose administered was said to be the same as for the first two vaccinations. The study was carried out during a period in which Delta was the predominant virus variant, explained Biontech and Pfizer. All study participants had been vaccinated twice with the Pfizer Biontech vaccine prior to the start of the study. Their average age was 53 years. There was an average of eleven months between the second vaccination and the booster.
During the study period, there were reportedly five Covid-19 cases in the booster group, while 109 cases occurred in the placebo group.
Pharma companies speak of “advantage”
“These results are further evidence of the benefits of boosters,” said Pfizer CEO Albert Bourla. “This important data complements the evidence that a booster dose of our vaccine can help protect a broad population from this virus and its variants,” added Biontech chief and co-founder Ugur Sahin. “Based on these results, we believe that booster vaccinations, along with widespread global access to vaccines for all, could play an important role in containing the pandemic and returning to normal.”
Refreshing with Moderna vaccine is before a decision
While the refreshment with the vaccine from Biontech / Pfizer is already being carried out in everyday life, other vaccines are still being tested. The European Medicines Agency (EMA) is expected to announce the result of its review of the booster vaccination of Moderna on October 25th. This is announced by the authority. At the same time, testing of the drug Molnupiravir should start next week.
Approval of Sputnik V is not expected until 2022
The EMA has been advising for a long time about the general approval of the Russian Covid-19 vaccine Sputnik V. This will be granted in early 2022 at the earliest. An audit by the end of the year is impossible because there is still a lack of data. If these are submitted by the end of November, the EMA could complete the examination in the first quarter of 2022, said the insider.
First stitch with Russian vaccine has to wait in the EU
The examination of Sputnik V was initiated in March. A decision was expected in May or June. According to information from Russian government circles, there are technological differences between Russia and the EMA regarding the completeness of the data. The EMA announced at the beginning of September that it was expecting further information on the production of Sputnik V. According to the insider, in addition to the production of the active ingredient, this also applies to the filling of the finished vaccine.
In February the trade magazine had „The Lancet“ the results of phase III tests of Sputnik V published. After that, the vaccine is almost 92 percent effective. According to later Russian information, Sputnik V also has an effectiveness of 83 percent against the more contagious Delta variant of the virus.
Sputnik already in use in more than 70 non-EU countries
The vaccine is widely used in Russia and is approved in more than 70 countries. EU approval would be a great relief for Russians who want to travel to the European Union. Only vaccines approved by the EMA or the World Health Organization are recognized there.